Edition:
India

Aquestive Therapeutics Inc (AQST.OQ)

AQST.OQ on NASDAQ Stock Exchange Global Market

5.78USD
2:29am IST
Change (% chg)

$0.34 (+6.25%)
Prev Close
$5.44
Open
$5.50
Day's High
$5.90
Day's Low
$5.50
Volume
118,927
Avg. Vol
34,883
52-wk High
$16.19
52-wk Low
$2.96

Latest Key Developments (Source: Significant Developments)

Intelgenx, Aquestive Therapeutics Enter Collaboration Agreement For Tadalafil
Wednesday, 8 May 2019 

May 8 (Reuters) - Aquestive Therapeutics Inc ::INTELGENX AND AQUESTIVE THERAPEUTICS ENTER WORLDWIDE COLLABORATION AGREEMENT FOR TADALAFIL.INTELGENX TECHNOLOGIES CORP - INTELGENX AND AQUESTIVE WILL EACH GRANT TO OTHER EXCLUSIVE WORLDWIDE LICENSES TO THEIR RESPECTIVE INTELLECTUAL PROPERTY.INTELGENX TECHNOLOGIES CORP - DEAL FOR EXCLUSIVE WORLDWIDE LICENSES PROPERTY RELATING TO TADALAFIL ORAL FILM FORMULATION AND MANUFACTURING.INTELGENX TECHNOLOGIES CORP - INTELGENX WILL PAY AQUESTIVE A ROYALTY EQUAL TO 10% OF ALL PAYMENTS RECEIVED BY INTELGENX.  Full Article

Aquestive Therapeutics Announces U.S. FDA Acceptance Of New Drug Application For ALS Oral Treatment
Tuesday, 16 Apr 2019 

April 16 (Reuters) - Aquestive Therapeutics Inc ::AQUESTIVE THERAPEUTICS ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTANCE OF NEW DRUG APPLICATION FOR RILUZOLE ORAL FILM FOR TREATMENT OF ALS.AQUESTIVE THERAPEUTICS INC - PDUFA (PRESCRIPTION DRUG USER FEE ACT) GOAL DATE IS NOVEMBER 30, 2019.AQUESTIVE THERAPEUTICS INC - COMPANY IS EXPLORING COMMERCIAL OPPORTUNITIES FOR ROF IN U.S. AND ABROAD..  Full Article

Aquestive Therapeutics Q4 Loss Per Share $0.56
Thursday, 14 Mar 2019 

March 14 (Reuters) - Aquestive Therapeutics Inc ::AQUESTIVE THERAPEUTICS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.Q4 REVENUE $16.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $16.7 MILLION.Q4 LOSS PER SHARE $0.56.Q4 EARNINGS PER SHARE ESTIMATE $-0.51 -- REFINITIV IBES DATA.SEES FULL YEAR 2019 TOTAL REVENUES OF $33 MILLION TO $45 MILLION.SEES FULL YEAR 2019 NON-GAAP ADJUSTED EBITDA LOSS OF $40 MILLION TO $45 MILLION.SEES FULL YEAR 2019 CASH BURN OF APPROXIMATELY $45 MILLION TO $50 MILLION.  Full Article

Aquestive Therapeutics Granted Temporary Restraining Order Against Alvogen
Friday, 25 Jan 2019 

Jan 25 (Reuters) - Aquestive Therapeutics Inc ::AQUESTIVE THERAPEUTICS GRANTED TEMPORARY RESTRAINING ORDER (TRO) AGAINST ALVOGEN.AQUESTIVE THERAPEUTICS - TRO TO REMAIN IN PLACE PENDING HEARING ON PRELIM. INJUNCTION MOTION PREVIOUSLY FILED BY CO, INDIVIOR.AQUESTIVE THERAPEUTICS - TRO ENJOINS ALVOGEN FROM INITIATING ANY LAUNCH ACTIVITIES RELATED TO ITS GENERIC BUPRENORPHINE/NALOXONE SUBLINGUAL FILM.AQUESTIVE THERAPEUTICS INC - HEARING ON PI MOTION IS SCHEDULED WITH DISTRICT COURT ON FEBRUARY 7, 2019.  Full Article

Aquestive Therapeutics Launches Sympazan Oral Film With Widespread U.S. Availability
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - Aquestive Therapeutics Inc ::AQUESTIVE THERAPEUTICS LAUNCHES SYMPAZAN™ (CLOBAZAM) ORAL FILM WITH WIDESPREAD U.S. AVAILABILITY.  Full Article

Aquestive Therapeutics Gets Tentative FDA Approval For Sympazan (Clobazam) Oral Film
Saturday, 1 Sep 2018 

Aug 31 (Reuters) - Aquestive Therapeutics Inc ::AQUESTIVE THERAPEUTICS ANNOUNCES TENTATIVE FDA APPROVAL FOR SYMPAZAN (CLOBAZAM) ORAL FILM.SAYS FINAL FDA APPROVAL FOR SYMPAZAN PENDING EXPIRATION OF ORPHAN DRUG EXCLUSIVITY PERIOD FOR ONFI, EXPECTED IN OCT.  Full Article